OBJECTIVES: Whole genome sequencing (WGS) can be used to predict future disease risk or inform treatment. Current guidelines suggest only reporting variants that are clinically actionable. Reporting incidental or non-actionable findings could generate anxiety and unnecessary medical tests, but patients could miss valuable information if not reported. Over-treatment may occur by acting on findings prematurely, potentially causing harm and unnecessary resource use. We measure the value of WGS information using contingent valuation methods.  METHODS: An online pilot survey (n=26 adults from US general population) was used to evaluate willingness to pay for a basic WGS report (recommended by guidelines), and genetic information excluded from the basic report (non-actionable findings) to inform a national survey.  Respondents were initially asked whether they would purchase a basic WGS report for a specified dollar amount. A follow-up question increased or decreased cost of the report based on the initial response. Responses were used to identify ranges of willingness to pay for a basic report for each respondent. The same steps were followed to identify ranges for respondents’ willingness to pay for information excluded from the WGS report. The initial costs in the questions were randomized across respondents.  RESULTS: